Drugs / ALT-BB4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05232175 | Jan → Aug 2022 | — | Alteogen, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALT-BB4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05232175 ↗ |
| Modality | Protein / enzyme biologic | “ALT-BB4, a novel recombinant hyaluronidase derived from human hyaluronidase PH20” PMID 40892310 ↗ Sep 2025 |
| Route | Subcutaneous | “single intradermal or subcutaneous injections of ALT-BB4 or placebo” PMID 40892310 ↗ Sep 2025 |